Curve Beam AI receives an institutional placement commitment of $6.5 mln at $0.09 per share

delay Australian SE			5-day changes	Changes from January 1st
0.0960 ^aud	-12.73%		-16.52%	-28.89%

10:37pm EDT published on 28/09/2025

Reuters

This article has been reserved member

Unlock Articles: Sign up now!

©Reuters -2025

Curve Beam AI receives an institutional placement commitment of $6.5 mln at $0.09 per share	10:37pm	Re
Curve Beam AI to increase $6.5 million with placement. Stocks will decline by 15%	10:09pm	mountain
Curve Beam AI is seeking to stop trading	September 24th	Re
Curve Beam AI Limited Report Full-year revenue results ended June 30, 2025	August 28th	CI
Curvebeam AI says there is a year loss that caused $16.8 million	August 27th	Re
Curvebeam AI Limited Auditor raises “concernable” suspicions	August 26th	CI
The 11,193,732 Curve Beam AI Limited option is subject to a lockup agreement that terminates on 22-AUG-2025.	August 21st	CI
67,993,892 Curvebeam AI Limited's common stock is subject to a lockup agreement terminated at 22-AUG-2025.	August 21st	CI
CurveBeam AI Limited, Q4 2025 Revenue Call, July 30, 2025	July 30th
CurveBeam AI Limited, Q3 2025 Revenue Call, April 30, 2025	June 9th
Curve Beam AI does not see any significant impacts from US tariffs. 6% sharing	April 7th	mountain
Curve Beam AI does not expect material adverse effects from US tariffs	April 7th	Re
Curve Beam AI Limited announces vendor verification of the enhanced Hilis of the robotic surgical system in the final stage	March 30th	CI
Curve Beam AI Limited Report Six-month revenue results ended December 31, 2024	February 27th	CI
CurveBeam AI Limited, Q2 2025 Revenue Call, January 29, 2025	January 28th
Curve Beam AI signs commercial transactions with medical device manufacturers. 4% decrease	January 27th	mountain
CurveBeam AI Limited – Shareholder/Analyst Call	November 25th
CurveBeam AI Limited, Q1 2025 Revenue Call, October 31, 2024	24-10-30
Curve Beam AI Limited Report Full-year revenue results ended June 30, 2024	24-08-28	CI
The rights to 43,750 Curve Beam AI Limited are subject to a lockup agreement terminating at 22-AUG-2024.	24-08-21	CI
33,481,162 Curvebeam AI Limited's common stock is subject to a lockup agreement terminated at 15-AUG-2024.	24-08-14	CI
Curvebeam AI will launch AU$13.6 million shares. Stocks will decline by 19%	24-08-05	mountain
Curve Beam AI raises $13.6 million through placement, qualification offers	24-08-01	mountain
Curve Beam AI ensures FDA clearance for the CT scanner. 6% sharing	24-07-14	mountain
Curve beam ai order for US demand for 4th quarter	24-07-08	mountain

interval

period

CVB: Dynamic Chart

Curvebeam AI Ltd combines point-of-care diagnostic cone beam computed tomography (CT) imaging solutions with artificial intelligence (AI) and deep learning AI (DLA) expertise to provide solutions across orthopedic surgery and bone health (fragility fracture prevention). The company's orthopedic products include Hirise, Lineup, Pedcat Premium, Pedcat, Inreach, and Cubevue software. Its bone health products include InReach HR-PQCT and OSSVIEW. The system is available in multiple locations via a self-contained, easy-to-operate mobile imaging solution. Hirise is the weight band that holds weight on both sides of CT imaging of the entire lower limb, including the hip/pelvis and distal upper limb. The lineup is weight-resistant electrons on both sides of CT imaging of the distal lower and upper limbs. InReach HR-PQCT is a high-resolution peripheral quantitative CT (HR-PQCT) imaging system designed for point-of-care.

Company details

sell